Skip to content

Foster Kennedy Syndrome C0152112

Published: July 22, 2026Updated: August 27, 2026

A neurological condition causing vision loss and specific eye findings, usually from tumors or increased pressure in the brain. Outlook depends on the underlying cause.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
H47.141, H47.142, H47.143
ICD-11
9A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Vision loss

!

Papilledema

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Headache

(neurologic)

Anosmia

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Craniotomy with tumor resection

Surgical removal of the underlying frontal lobe tumor causing Foster-Kennedy syndrome is the definitive treatment and primary approach to prevent further neurological deterioration.

surgical

Additional treatment options

Stereotactic radiosurgery

For patients who are not surgical candidates, targeted radiation therapy can treat the tumor while minimizing damage to surrounding brain tissue.

procedure

Neuro-ophthalmologic surveillance

Regular ophthalmologic examinations to monitor optic atrophy progression and assess visual field defects, complementing treatment of the underlying cause.

monitoring

Corticosteroid therapy for cerebral edema

Dexamethasone or similar corticosteroids reduce peritumoral vasogenic edema, providing symptomatic relief of increased intracranial pressure symptoms.

medication

Neuropsychological rehabilitation support

Cognitive rehabilitation and psychological support help patients cope with potential personality changes, anosmia, and visual deficits associated with the condition and its treatment.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Foster Kennedy Syndrome C0152112?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Foster Kennedy Syndrome C0152112. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy